RESEARCH TRIANGLE PARK, N.C., U.S.A. (January 17, 2006)

  Qualyst, Inc. today announced that the Company will be hosting a reception and seminar in the San Francisco Bay Area on February 23, 2006. Industry experts will give insight as to the use of B-CLEAR® to predict hepatobiliary clearance and drug-drug interactions.

  "Due to the overwhelming response to Qualyst’s first seminar on predictive liver biliary clearance held in Cambridge, MA last fall, we are delighted to repeat this event on the west coast," said Scott E. Neuville, President and Chief Executive Officer of Qualyst. "Pharmaceutical and biotechnology researchers need effective in vitro methods to understand the role of hepatic drug transporters in drug bio-availability and safety. This reception will address B-CLEAR® and its use in discovery as a screen and a source of lead optimization guidance, and in development as a tool to address drug transport questions."

  B-CLEAR® is Qualyst’s patented in vitro sandwich-cultured hepatocyte system for the assessment of hepatobiliary disposition, biliary clearance and drug transport.

About Qualyst, Inc.
Qualyst commercializes novel and proprietary ADMET products for drug discovery and development. Qualystís products allow pharmaceutical and biotechnology researchers to make faster, better decisions regarding drug candidate compounds, saving valuable time and research dollars in the process. Qualyst, Inc. was founded on discoveries from breakthrough research at the University of North Carolina at Chapel Hill in 2001. For additional information, please refer to the company's web site at www.Qualyst.com or call 919-313-6500.

CONTACT:

Ian J. Mehr
Vice President, Business Development
Qualyst, Inc.
919-313-6507
info[AT]qualyst[DOT]com
www.Qualyst.com